Innate Pharma Strengthens Its Platform In The Pharmacology Of Toll-Like Receptors (TLR) With Assets Licensed From US-Based Global Pharmaceutical Company Schering-Plough Corporation

MARSEILLE, France--(BUSINESS WIRE)--June 19, 2006--Innate Pharma Strengthens Its Platform in the Pharmacology of Toll-Like Receptors (TLR): Innate Pharma S.A., a biopharmaceutical company that develops new classes of drug candidates targeting the innate immune system, with an initial focus on cancer diseases, today announced the strengthening of its product platform based on the pharmacological manipulation of Toll-like receptors (TLRs) with the in-licensing of key assets from US group Schering-Plough Corporation and the signature of an advanced R&D collaboration, in the field, with "Institut de cancerologie Gustave-Roussy" (or "IGR"), France's largest cancer center.